top of page
The Professional Network for Healthcare Experts
Ascendis and BioMarin agree global Yuviwel patent settlement and licence
The binding term sheet resolves litigation between Ascendis Pharma and BioMarin while granting Ascendis a worldwide licence covering YUVIWEL and other navepegritide-related products.
nuaxia
Sep 12 min read
BioMarin to acquire Alesta Therapeutics in deal worth up to $490 million for Phase I/II hypophosphatasia therapy
The acquisition gives BioMarin access to ALE1, a potential first oral treatment for hypophosphatasia, while expanding its rare disease pipeline with a clinical-stage skeletal disease programme.
nuaxia
Aug 202 min read
bottom of page